Accordingly, in our hands extended rapamycin treatment of fibroblasts (MEFs), and pancreatic endocrine tumor cells (BON1), potently reduced cell migration only in the presence of menin, whereas low levels or complete lack of menin decreased the effects of rapamycin. The gene discussed is MEN1; the disease is pancreatic neuroendocrine tumor.